Cargando…
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
Monoclonal antibodies (mAb) are revolutionising the treatment of many different diseases. Given their differing mode of action compared to most conventional chemotherapeutics and small molecule inhibitors, they possess the potential to be independent of common modes of treatment resistance and can t...
Autores principales: | Stopforth, Richard J., Cleary, Kirstie L. S., Cragg, Mark S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891381/ https://www.ncbi.nlm.nih.gov/pubmed/26922075 http://dx.doi.org/10.1007/s10875-016-0247-8 |
Ejemplares similares
-
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
por: Hussain, Khiyam, et al.
Publicado: (2022) -
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019) -
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
por: Simpson, Alexander P., et al.
Publicado: (2022) -
Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking
por: Liu, Luyan, et al.
Publicado: (2022) -
The Complex Association of FcγRIIb With Autoimmune Susceptibility
por: Verbeek, J. Sjef, et al.
Publicado: (2019)